BAT's restructuring excludes the US, where licensing delays for Vuse and Velo constrain sales. The stock's path hinges on regulatory approvals. Accenture gains a contract.
Alpha Score of 45 reflects weak overall profile with poor momentum, strong value, moderate quality, moderate sentiment.
British American Tobacco said Monday it will cut 5,500 jobs and move 3,500 roles to third-party firms, including Accenture. The total affected workforce is about 9,000, or roughly 20% of employees outside the US. The restructuring excludes its largest market by revenue.
The cost-saving programme targets £600 million ($793 million) in annualised incremental savings by 2028. BAT already has £500 million of that planned by 2027. The company signalled the possibility of cuts in February and left its group-wide guidance unchanged in June, suggesting the programme was already baked into expectations.
The pressure to cut costs stems partly from a slow roll-out of new nicotine products in the US. Manufacturers like BAT, which sells Vuse vapes and Velo nicotine pouches, must obtain a licence from regulators before launching new products. The process has been lengthy and has delayed releases, constraining sales growth in the country. BAT said most of the role changes have been confirmed with employees. Remaining consultations are ongoing and follow local requirements.
The job cuts and outsourcing will reduce operating costs and improve margins. The £600 million in annual savings by 2028 is significant relative to BAT's current cost base. Still, the core challenge for the stock remains the US regulatory bottleneck. Without new product launches, revenue growth is capped. The licensing process has been slow, and the FDA has shown caution. If approvals come through, BAT could see a revenue boost. If not, cost cuts alone may not sustain the stock.
For Accenture, the contract adds a stream of work but is unlikely to move the needle on its own. The consulting firm's Alpha Score is 45 out of 100 in AlphaScala's model, a neutral reading that reflects a business with steady cash flows but limited near-term catalysts. The ACN stock page shows the stock has been range-bound.
BAT has not provided a timeline for when US licensing approvals might come.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.